Analyst Ratings for BioMarin Pharmaceutical Inc. (bmrn)
bmrn Rating Summary
bmrn Price Target Summary
- Highest: $77.00 (Lazard Capital)
- Lowest: $36.00 (RBC Capital)
- Average: $58.80
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$58.80 (+2.8%)
Avg. $ Target:
$58.80 (+2.8%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/3/2013 | Deutsche Bank | Upgrade | Buy (Hold) |
75.00 (N/A) |
62.70 | 57.21 | -8.76% | Details |
| 1/22/2013 | Stifel Nicolaus | Upgrade | Buy (Hold) |
67.00 (N/A) |
54.08 | 57.21 | 5.79% | Details |
| 1/3/2013 | Janney Montgomery Scott | New Coverage | Buy (N/A) |
60.00 (N/A) |
51.92 | 57.21 | 10.19% | Details |
| 11/6/2012 | Brean Capital | Downgrade | Hold (Buy) |
N/A (N/A) |
37.41 | 57.21 | 52.93% | Details |
| 8/24/2012 | Barclays | New Coverage | Overweight (N/A) |
46.00 (N/A) |
37.94 | 57.21 | 50.79% | Details |
| 8/7/2012 | Lazard Capital » Updated 4/18/2013 |
New Coverage | Buy (N/A) |
77.00 (71.00) |
37.47 | 57.21 | 52.68% | Details |
| 6/29/2012 | ThinkEquity | New Coverage | Buy (N/A) |
44.00 (N/A) |
37.66 | 57.21 | 51.91% | Details |
| 4/12/2012 | UBS | New Coverage | Buy (N/A) |
43.00 (N/A) |
32.28 | 57.21 | 77.23% | Details |
| 3/26/2012 | Canaccord Genuity » Updated 9/5/2012 |
New Coverage | Buy (N/A) |
52.00 (N/A) |
34.30 | 57.21 | 66.79% | Details |
| 2/22/2012 | Citi | New Coverage | Buy (N/A) |
45.00 (N/A) |
35.26 | 57.21 | 62.25% | Details |
| 9/16/2011 | RBC Capital | New Coverage | Outperform (N/A) |
36.00 (N/A) |
30.35 | 57.21 | 88.5% | Details |
| 8/10/2011 | Piper Jaffray » Updated 3/20/2013 |
Upgrade | Overweight (N/A) |
70.00 (64.00) |
25.68 | 57.21 | 122.78% | Details |
| 11/1/2010 | Morgan Joseph | Downgrade | Hold (N/A) |
N/A (N/A) |
26.11 | 57.21 | 119.11% | Details |
| 10/18/2010 | Gleacher & Co. | New Coverage | Neutral (N/A) |
N/A (N/A) |
21.97 | 57.21 | 160.4% | Details |
